REG - Oncimmune Hldgs PLC - Results from COVID-19 autoantibody profiling panel

Oncimmune HoldingsAnnouncement

31/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211231:nRSe1002Xa&default-theme=true

RNS Number : 1002X  Oncimmune Holdings PLC  31 December 2021

31 December 2021

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Publication of results from ImmunoINSIGHTS COVID-19 autoantibody profiling
panel

 

Follows research collaboration with the Smidt Heart Institute at Cedars-Sinai
Medical Center

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces the publication of a paper entitled: "Paradoxical
sex-specific patterns of autoantibody response to SARS-CoV-2 infection" (1)
arising from the research collaboration between Oncimmune and Cedars-Sinai
Medical Center in Los Angeles ("Cedars-Sinai"). The paper focuses on the
sex-specific autoimmune reactivity to SARS-CoV-2 following mildly symptomatic
infection as well as the prolonged effects of COVID-19 well beyond the initial
infection and recovery phase.

 

This collaborative study focused on gaining an understanding of how COVID-19
infection affects a person's immune system in ways that might persist over
time. The research discovered that COVID-19 can trigger a broad autoantibody
response that can last well beyond the initial infection and recovery phase,
even among individuals who were only mildly affected or without any symptoms
at all.

 

The research team used Oncimmune's COVID-19 autoantibody profiling panel, an
advanced panel of serological measures to understand which parts of the
adaptive immune system are still activated for up to six months following full
apparent recovery from the initial COVID-19 infection. The results showed that
a wide array of autoantibodies remain elevated, including those linked to
autoimmune conditions such as lupus and rheumatoid arthritis.

 

The study, published in the Journal of Translational Medicine, suggests that
COVID-19 infection leads to a persistent activation of antibodies against
multiple different organ systems and tissues, many of which have been linked
to classic autoimmune diseases that typically affect women more than men. In
this research, however, men were more affected than women. This latest study
is the first to report both the presence of elevated autoantibodies after mild
or asymptomatic infection and their persistence over time.

 

Dr Adam M Hill, CEO of Oncimmune said: "As the life science industry continues
to work intensely to research and respond to the effects of COVID-19, and
specifically to understand the immune system response to the disease, we are
delighted to see this publication that further validates the ImmunoINSIGHTS
Infectious Diseases panel and contributes to the knowledge base so that
clinical outcomes from the disease can improve."

 

(1.) https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-03184-8

 

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
Oncimmune has a diversified and growing revenue base both from its contract
discovery and development service business whose platform delivers actionable
insights into therapies to the Company's pharmaceutical and biotech partners
as well as its portfolio of diagnostic products to detect early-stage cancer.

 

Our understanding of the immune system enables us to harness its sophisticated
response to disease to detect cancer earlier and to support the development of
better therapies. The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our passion to
improve cancer survival and to give people extra time.

 

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to
optimise drug development and delivery, leading to more effectively targeted
and safer treatments for patients. Oncimmune's immunodiagnostic technology,
EarlyCDT, can detect and help identify cancer on average four years earlier
than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000
tests already performed for patients worldwide and its use being supported by
peer reviewed data in over 12,000 patients, we are poised to become an
integral component of future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery
research centre in Dortmund, Germany. The ImmunoINSIGHTS business development
team are based in the US and Europe and Oncimmune is seeking to replicate the
Dortmund facility in the US in the medium term.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

What is ImmunoINSIGHTS?

 

The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAKAEDAFFFFA